ERBB2 and non-small cell lung carcinoma: This field is getting even more complex as new mutations and expressions are still being identified and innovative therapies are emerging within the field of NSCLC, such as treatments for the mutations or expressions BRAF, HER2, HER3, KRAS, MET, NTRK, RET, and TROP2.